Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/199943
Type: Artigo de periódico
Title: Recombinant Factor Viia Analog (vatreptacog Alfa [activated]) For Treatment Of Joint Bleeds In Hemophilia Patients With Inhibitors: A Randomized Controlled Trial.
Author: de Paula, Erich V
Kavakli, Kaan
Mahlangu, Johnny
Ayob, Yasmin
Lentz, Steven R
Morfini, Massimo
Nemes, László
Šalek, Silva Z
Shima, Midori
Windyga, Jerzy
Ehrenforth, Silke
Chuansumrit, Ampaiwan
,
Abstract: A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors. This global, prospective, randomized, double-blinded, active-controlled, dose-escalation trial evaluated and compared one to three doses of vatreptacog alfa at 5, 10, 20, 40, and 80 lg kg(-1) with one to three doses of recombinant FVIIa (rFVIIa) at 90 lg kg(-1) in the treatment of acute joint bleeds in hemophilia patients with inhibitors. The primary endpoint comprised adverse events; secondary endpoints were evaluations of immunogenicity, pharmacokinetics, and efficacy. Overall, 96 joint bleeds in 51 patients (> 12 years of age) were dosed. Vatreptacog alfa was well tolerated, with a low frequency of adverse events. No immunogenic or thrombotic events related to vatreptacog alfa were reported. A high efficacy rate of vatreptacog alfa in controlling acute joint bleeds was observed; 98% of bleeds were controlled within 9 h of the initial dose in a combined evaluation of 20–80 lg kg(-1) vatreptacog alfa. The efficacy rate observed for rFVIIa (90%) is consistent with data from published clinical trials. The trial was not powered to compare efficacy, and further trials are needed to investigate the efficacy of vatreptacog alfa as compared with that of rFVIIa. The trial was registered at ClinicalTrials.gov ( NCT00486278).
Subject: Adolescent
Adult
Autoantibodies
Dose-response Relationship, Drug
Double-blind Method
Factor Viia
Hemarthrosis
Hemophilia A
Humans
Recombinant Proteins
Treatment Outcome
Young Adult
Rights: fechado
Identifier DOI: 
Address: http://www.ncbi.nlm.nih.gov/pubmed/22470921
Date Issue: 2012
Appears in Collections:Artigos e Materiais de Revistas Científicas - Unicamp

Files in This Item:
File SizeFormat 
pmed_22470921.pdf231.49 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.